<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR31">
 <label>31.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Antonia</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Goldberg</surname>
    <given-names>SB</given-names>
   </name>
   <name>
    <surname>Balmanoukian</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Chaft</surname>
    <given-names>JE</given-names>
   </name>
   <name>
    <surname>Sanborn</surname>
    <given-names>RE</given-names>
   </name>
   <name>
    <surname>Gupta</surname>
    <given-names>A</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study</article-title>
  <source>Lancet Oncol</source>
  <year>2016</year>
  <volume>17</volume>
  <fpage>299</fpage>
  <lpage>308</lpage>
  <pub-id pub-id-type="doi">10.1016/S1470-2045(15)00544-6</pub-id>
  <?supplied-pmid 26858122?>
  <pub-id pub-id-type="pmid">26858122</pub-id>
 </element-citation>
</ref>
